Verona Pharma PLC
NASDAQ:VRNA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.48
39.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one VRNA stock under the Base Case scenario is 15.98 USD. Compared to the current market price of 38.81 USD, Verona Pharma PLC is Overvalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Verona Pharma PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for VRNA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Verona Pharma PLC
Balance Sheet Decomposition
Verona Pharma PLC
Current Assets | 364.3m |
Cash & Short-Term Investments | 336m |
Receivables | 12.5m |
Other Current Assets | 15.7m |
Non-Current Assets | 17.6m |
Long-Term Investments | 15m |
PP&E | 2m |
Intangibles | 545k |
Current Liabilities | 28m |
Accounts Payable | 6.8m |
Accrued Liabilities | 19.1m |
Other Current Liabilities | 2m |
Non-Current Liabilities | 223.4m |
Long-Term Debt | 120m |
Other Non-Current Liabilities | 103.4m |
Earnings Waterfall
Verona Pharma PLC
Revenue
|
5.6m
USD
|
Cost of Revenue
|
-543k
USD
|
Gross Profit
|
5.1m
USD
|
Operating Expenses
|
-160.5m
USD
|
Operating Income
|
-155.4m
USD
|
Other Expenses
|
1.7m
USD
|
Net Income
|
-153.7m
USD
|
Free Cash Flow Analysis
Verona Pharma PLC
USD | |
Free Cash Flow | USD |
In Q3 2024, Verona Pharma successfully launched Ohtuvayre for COPD, achieving $5.6 million in net sales within seven weeks. Ohtuvayre has gained traction, with October sales surpassing Q3 figures and prescriptions exceeding 5,000. Approximately 30% of leading prescribers have already adopted the drug. The company is optimistic about ongoing Phase II trials and anticipates significant revenue growth throughout 2025, capitalizing on its strong cash position of $336 million. However, losses widened to $43 million compared to $14.7 million the previous year, reflecting increased R&D and commercial expenses.
What is Earnings Call?
VRNA Profitability Score
Profitability Due Diligence
Verona Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Verona Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
VRNA Solvency Score
Solvency Due Diligence
Verona Pharma PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Verona Pharma PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRNA Price Targets Summary
Verona Pharma PLC
According to Wall Street analysts, the average 1-year price target for VRNA is 46.73 USD with a low forecast of 36.36 USD and a high forecast of 67.2 USD.
Dividends
Current shareholder yield for VRNA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
VRNA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.
Contact
IPO
Employees
Officers
The intrinsic value of one VRNA stock under the Base Case scenario is 15.98 USD.
Compared to the current market price of 38.81 USD, Verona Pharma PLC is Overvalued by 59%.